Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Reunion Neuroscience Inc T.REUN

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.


TSX:REUN - Post by User

Post by evilballson Feb 22, 2021 10:48pm
317 Views
Post# 32633875

$8 level seems to have been attained

$8 level seems to have been attainedI have a firm beleif this is a billion dollar company this year.  The only area where they are receiving any type of poor marks is their app.

 A minimum 20 treatment centers within the year.  5 up and running, 3 in the process and another 12 over the next year.  1 a month.  They have a budget to do as many as 30 wtih $30M in the kitty and a whole bunch of warrants $5.60 strike price to cash up if needed.  These are revenue generating which is certainly something that attracts me.  Not many of these mushroom companies will be generating revenue. I am actually pretty excited to see next quarters revenues.  REvenue numbers quadrupled quarter over quarter and will probably maintain that type of trajectory.

That other comapny certainly does not have the growth profile FTRP has. The fact that they are concentrarting the US market with a Toronto Center and one in the Netherlands keeps them firmly planted in all major markets. 
<< Previous
Bullboard Posts
Next >>